The FDA has approved a new Alzheimer’s drug. The new treatment by Eli Lilly will be sold under the brand name Kisunla, and was approved Tuesday by the FDA after outside experts said the benefits of the drug outweighed its risks. The drug is designed to clear the brain of an Alzheimer’s-related protein called beta amyloid. In a late-stage trial, the drug slowed the progression of memory problems by 29% compared with a placebo. Lilly is charging about 700-dollars a vial for the drug, or 32-thousand dollars for a 12-month treatment.
***Courtesy of Total Traffic News***
